Tuesday, 18 January 2022

Tag Archives: Generic drugmaker

Mylan NV shares slide after warning of hit to revenue

MORGANTOWN: Generic drugmaker Mylan NV said reevaluation of its portfolio of medicines will continue next year and cautioned of a hit to revenue, and its shares nearly 6%. Mylan, which posted higher-than-expected third-quarter profit with the help of cost constraints, said it would reassess products it sells outside United States ...

Read More »